Zenas BioPharma
Executive Summary
Zenas BioPharma is a dual-headquartered biotech with operations in Waltham and Shanghai, positioning it at the intersection of US and Chinese markets. The company appears to be BIOSECURE-compliant with clear status, making it a viable partner for US pharma deals. Limited public information suggests a focus on maintaining regulatory compliance while developing its pipeline, though specific therapeutic areas and deal-making history require further investigation.
Structure: As a US-listed biotech (ZBIO) with Shanghai operations, Zenas likely employs a complex structure involving US holding companies and Chinese operating entities. The 10-K filing mentions VIE disclosures, indicating potential Variable Interest Entity arrangements typical of US-listed Chinese biotech companies. Due diligence should focus on understanding the specific VIE structure and how IP and operations are distributed between jurisdictions.
Ownership & Shareholder Structure
Corporate Events
Zenas BioPharma 10-K Annual Report
10-K annual report filed with SEC. Contains corporate structure, VIE disclosures, and risk factors.
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, indicating proactive compliance efforts
Key Exposures:
- •Shanghai operations may involve Chinese personnel or facilities
- •Potential supply chain dependencies in China
- •VIE structure may involve Chinese regulatory oversight
Mitigation: Company appears to have addressed BIOSECURE concerns given its clear status, likely through operational restructuring or compliance measures
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity identified in available data
Approach: Approach with interest in their dual-market positioning and BIOSECURE-compliant structure, but conduct thorough pipeline due diligence given limited public information
Red Flags
- ⚠Limited public disclosure of key management and pipeline details
- ⚠VIE structure complexity requires careful legal review
- ⚠Dual-jurisdiction operations may create regulatory compliance challenges
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 1
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.